Drug intelligence / Profile preview

Hyal-Phage P

Development stage: Preclinical
Lead developer: iNtRON Biotechnology
Administration: Subcutaneous

Overview

Hyal-Phage P is an experimental drug candidate developed by iNtRON Biotechnology using its proprietary IMPA™ (Intelligent Micro-Phage Application) platform. It utilizes engineered bacteriophages as a delivery vehicle for hyaluronidase to the subcutaneous tissue. The primary objective of this platform is to enhance the absorption and dispersion of co-administered subcutaneous injections by breaking down hyaluronan in the extracellular matrix. This mechanism facilitates the delivery of large-volume or high-molecular-weight therapeutics that are otherwise difficult to administer via the subcutaneous route.

Beyond the preview

Go deeper on Hyal-Phage P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyal-Phage P.

Explore the full profile